 Megan Kelsey
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 39 | 2025 | 2516 | 4.210 |
Why?
| | Insulin Resistance | 17 | 2024 | 1222 | 3.320 |
Why?
| | Puberty | 11 | 2024 | 152 | 3.230 |
Why?
| | Pediatric Obesity | 14 | 2025 | 597 | 3.090 |
Why?
| | Hypoglycemic Agents | 9 | 2023 | 1343 | 1.600 |
Why?
| | Metformin | 7 | 2023 | 331 | 1.430 |
Why?
| | Bariatric Surgery | 7 | 2022 | 217 | 1.300 |
Why?
| | Adolescent | 60 | 2025 | 21581 | 1.270 |
Why?
| | Obesity, Morbid | 8 | 2022 | 271 | 1.270 |
Why?
| | Obesity | 17 | 2024 | 2994 | 1.270 |
Why?
| | Prediabetic State | 6 | 2021 | 248 | 1.170 |
Why?
| | Body Mass Index | 16 | 2025 | 2390 | 1.080 |
Why?
| | Testosterone | 7 | 2024 | 402 | 1.050 |
Why?
| | Insulin-Secreting Cells | 3 | 2021 | 374 | 0.950 |
Why?
| | Adolescent Behavior | 3 | 2020 | 533 | 0.860 |
Why?
| | Health Behavior | 3 | 2020 | 780 | 0.840 |
Why?
| | Child | 41 | 2025 | 21936 | 0.790 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.750 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 18 | 0.740 |
Why?
| | Blood Glucose | 13 | 2023 | 2241 | 0.740 |
Why?
| | Body Composition | 4 | 2021 | 695 | 0.730 |
Why?
| | Transgender Persons | 2 | 2024 | 187 | 0.680 |
Why?
| | Cardiovascular Diseases | 7 | 2023 | 2058 | 0.650 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.580 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 140 | 0.570 |
Why?
| | Female | 53 | 2025 | 74016 | 0.560 |
Why?
| | Polycystic Ovary Syndrome | 4 | 2021 | 177 | 0.550 |
Why?
| | Insulin | 6 | 2021 | 2447 | 0.550 |
Why?
| | Humans | 71 | 2025 | 138972 | 0.540 |
Why?
| | Adipose Tissue | 3 | 2021 | 645 | 0.540 |
Why?
| | Male | 44 | 2025 | 68250 | 0.520 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1034 | 0.500 |
Why?
| | Body Weight | 1 | 2020 | 996 | 0.490 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 366 | 0.480 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2022 | 3705 | 0.440 |
Why?
| | Depression | 3 | 2024 | 1470 | 0.430 |
Why?
| | Sex Factors | 4 | 2019 | 2050 | 0.420 |
Why?
| | Muscle Fatigue | 1 | 2014 | 97 | 0.400 |
Why?
| | Leptin | 1 | 2015 | 242 | 0.400 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5530 | 0.400 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 191 | 0.390 |
Why?
| | Anti-Obesity Agents | 2 | 2025 | 57 | 0.390 |
Why?
| | Thinness | 1 | 2013 | 95 | 0.390 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1267 | 0.380 |
Why?
| | Disease Progression | 1 | 2020 | 2752 | 0.370 |
Why?
| | Off-Label Use | 2 | 2022 | 53 | 0.360 |
Why?
| | Mass Screening | 3 | 2022 | 1296 | 0.350 |
Why?
| | Biomarkers | 4 | 2020 | 4095 | 0.330 |
Why?
| | Cohort Studies | 8 | 2021 | 5744 | 0.320 |
Why?
| | Life Style | 4 | 2021 | 484 | 0.320 |
Why?
| | Metabolic Syndrome | 4 | 2020 | 346 | 0.320 |
Why?
| | Sleep | 3 | 2024 | 800 | 0.310 |
Why?
| | Androgens | 2 | 2022 | 186 | 0.300 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 54 | 0.300 |
Why?
| | Reference Values | 2 | 2020 | 801 | 0.290 |
Why?
| | Muscle, Skeletal | 3 | 2014 | 1734 | 0.280 |
Why?
| | Ribonuclease III | 2 | 2021 | 40 | 0.280 |
Why?
| | Receptor, Melanocortin, Type 4 | 2 | 2024 | 17 | 0.270 |
Why?
| | Bone Density | 2 | 2023 | 489 | 0.270 |
Why?
| | Weight Gain | 2 | 2022 | 538 | 0.270 |
Why?
| | Estradiol | 3 | 2022 | 525 | 0.270 |
Why?
| | DEAD-box RNA Helicases | 2 | 2021 | 74 | 0.270 |
Why?
| | Case-Control Studies | 6 | 2021 | 3574 | 0.250 |
Why?
| | Fructosamine | 2 | 2016 | 15 | 0.240 |
Why?
| | Pituitary Neoplasms | 2 | 2021 | 191 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2016 | 50 | 0.240 |
Why?
| | Risk Factors | 8 | 2024 | 10385 | 0.240 |
Why?
| | Phentermine | 1 | 2025 | 12 | 0.230 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 322 | 0.230 |
Why?
| | Serum Albumin | 2 | 2016 | 151 | 0.230 |
Why?
| | alpha-MSH | 1 | 2024 | 5 | 0.230 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2850 | 0.220 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5152 | 0.220 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 57 | 0.210 |
Why?
| | Young Adult | 10 | 2023 | 13371 | 0.210 |
Why?
| | Endocrinology | 1 | 2024 | 76 | 0.210 |
Why?
| | Age Factors | 3 | 2021 | 3276 | 0.210 |
Why?
| | Radius | 2 | 2023 | 51 | 0.210 |
Why?
| | Glucose Clamp Technique | 2 | 2015 | 196 | 0.200 |
Why?
| | Aging | 1 | 2014 | 1857 | 0.200 |
Why?
| | Hypoglycemia | 2 | 2019 | 460 | 0.200 |
Why?
| | Treatment Outcome | 8 | 2025 | 10921 | 0.200 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.200 |
Why?
| | Drug Therapy, Combination | 3 | 2025 | 1031 | 0.190 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 699 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1522 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 48 | 0.190 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 170 | 0.180 |
Why?
| | Colorado | 4 | 2020 | 4543 | 0.180 |
Why?
| | Bariatrics | 1 | 2021 | 5 | 0.180 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.180 |
Why?
| | Mindfulness | 1 | 2024 | 145 | 0.180 |
Why?
| | Hypertension | 2 | 2021 | 1249 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2024 | 299 | 0.170 |
Why?
| | Overnutrition | 1 | 2021 | 30 | 0.170 |
Why?
| | Blast Crisis | 1 | 2021 | 33 | 0.170 |
Why?
| | Hyperinsulinism | 1 | 2021 | 122 | 0.160 |
Why?
| | Hypogonadism | 1 | 2010 | 92 | 0.160 |
Why?
| | Bone and Bones | 1 | 2023 | 317 | 0.160 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 69 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 980 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2021 | 118 | 0.160 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 202 | 0.160 |
Why?
| | Cushing Syndrome | 1 | 2009 | 9 | 0.160 |
Why?
| | Prognosis | 4 | 2021 | 3995 | 0.160 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 516 | 0.160 |
Why?
| | Linear Models | 2 | 2019 | 855 | 0.160 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2009 | 11 | 0.160 |
Why?
| | Sexual Maturation | 1 | 2019 | 55 | 0.150 |
Why?
| | Growth Hormone | 1 | 2019 | 102 | 0.150 |
Why?
| | Pseudohypoaldosteronism | 1 | 2009 | 2 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 97 | 0.150 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 67 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 769 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2021 | 169 | 0.150 |
Why?
| | Research | 1 | 2022 | 451 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2019 | 51 | 0.150 |
Why?
| | Capillaries | 1 | 2019 | 114 | 0.150 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 110 | 0.150 |
Why?
| | Hyperkalemia | 1 | 2009 | 28 | 0.150 |
Why?
| | Analysis of Variance | 2 | 2019 | 1317 | 0.150 |
Why?
| | Gastrectomy | 1 | 2020 | 132 | 0.150 |
Why?
| | Time Factors | 3 | 2021 | 6869 | 0.150 |
Why?
| | Reproductive Health | 1 | 2019 | 91 | 0.150 |
Why?
| | Exercise | 3 | 2023 | 2086 | 0.150 |
Why?
| | Prospective Studies | 5 | 2021 | 7661 | 0.150 |
Why?
| | Pilot Projects | 2 | 2024 | 1765 | 0.140 |
Why?
| | Fatty Liver | 1 | 2021 | 230 | 0.140 |
Why?
| | Double-Blind Method | 2 | 2021 | 1949 | 0.140 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 118 | 0.140 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 83 | 0.140 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 74 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 216 | 0.140 |
Why?
| | Algorithms | 2 | 2024 | 1730 | 0.140 |
Why?
| | Exome | 1 | 2019 | 237 | 0.140 |
Why?
| | Diet | 2 | 2017 | 1285 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 368 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2025 | 15901 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 573 | 0.130 |
Why?
| | Adenoma | 1 | 2009 | 223 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2020 | 391 | 0.130 |
Why?
| | Human Development | 1 | 2016 | 16 | 0.130 |
Why?
| | Biodiversity | 1 | 2020 | 414 | 0.130 |
Why?
| | Adiposity | 1 | 2021 | 522 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 513 | 0.130 |
Why?
| | Weight Loss | 4 | 2025 | 783 | 0.120 |
Why?
| | Hydrocortisone | 1 | 2018 | 313 | 0.120 |
Why?
| | Adult | 10 | 2023 | 38393 | 0.120 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 299 | 0.120 |
Why?
| | Hyperglycemia | 2 | 2016 | 357 | 0.120 |
Why?
| | Triglycerides | 2 | 2020 | 513 | 0.120 |
Why?
| | United States | 8 | 2022 | 15074 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 611 | 0.110 |
Why?
| | Adiponectin | 1 | 2016 | 240 | 0.110 |
Why?
| | Risk | 1 | 2017 | 913 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2014 | 8 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2019 | 766 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 868 | 0.100 |
Why?
| | Lipolysis | 1 | 2013 | 46 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 22 | 0.100 |
Why?
| | Observer Variation | 1 | 2014 | 350 | 0.100 |
Why?
| | Fasting | 1 | 2014 | 283 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 61 | 0.100 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 158 | 0.100 |
Why?
| | Feeding Behavior | 1 | 2018 | 685 | 0.100 |
Why?
| | Nutrition Assessment | 1 | 2013 | 93 | 0.100 |
Why?
| | Adolescent Health Services | 1 | 2013 | 76 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1079 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 186 | 0.090 |
Why?
| | Electromyography | 1 | 2014 | 400 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 207 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1068 | 0.090 |
Why?
| | Muscle Contraction | 1 | 2014 | 432 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 817 | 0.090 |
Why?
| | Mutation | 3 | 2019 | 3984 | 0.080 |
Why?
| | Potassium Channels | 1 | 2011 | 149 | 0.080 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 264 | 0.080 |
Why?
| | Absorptiometry, Photon | 2 | 2023 | 263 | 0.080 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1391 | 0.080 |
Why?
| | Tibia | 2 | 2023 | 181 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2015 | 766 | 0.080 |
Why?
| | Child, Preschool | 5 | 2024 | 11158 | 0.080 |
Why?
| | C-Peptide | 2 | 2023 | 163 | 0.070 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2014 | 684 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2021 | 2716 | 0.070 |
Why?
| | Pregnancy | 4 | 2023 | 6870 | 0.070 |
Why?
| | Motor Activity | 1 | 2013 | 716 | 0.070 |
Why?
| | Glycation End Products, Advanced | 2 | 2016 | 83 | 0.060 |
Why?
| | Pro-Opiomelanocortin | 1 | 2024 | 20 | 0.060 |
Why?
| | Hyperphagia | 1 | 2024 | 40 | 0.060 |
Why?
| | Infant | 4 | 2021 | 9577 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2138 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 521 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 321 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1657 | 0.050 |
Why?
| | Treatment Failure | 1 | 2023 | 351 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2362 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2024 | 710 | 0.040 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2021 | 7 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 2021 | 22 | 0.040 |
Why?
| | Bacteroidetes | 1 | 2021 | 24 | 0.040 |
Why?
| | Firmicutes | 1 | 2021 | 19 | 0.040 |
Why?
| | Transferrin | 1 | 2021 | 50 | 0.040 |
Why?
| | Animals | 3 | 2019 | 37243 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 90 | 0.040 |
Why?
| | Health Education | 1 | 2024 | 360 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 292 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Waist Circumference | 1 | 2020 | 140 | 0.040 |
Why?
| | Heart | 1 | 2023 | 612 | 0.040 |
Why?
| | Mice, Obese | 1 | 2009 | 67 | 0.040 |
Why?
| | Fludrocortisone | 1 | 2009 | 2 | 0.040 |
Why?
| | Mineralocorticoids | 1 | 2009 | 7 | 0.040 |
Why?
| | Renin | 1 | 2009 | 35 | 0.040 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2009 | 21 | 0.040 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.040 |
Why?
| | Dissection | 1 | 2009 | 53 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 421 | 0.040 |
Why?
| | Craniotomy | 1 | 2009 | 79 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2009 | 150 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2021 | 188 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2687 | 0.040 |
Why?
| | Potassium | 1 | 2009 | 147 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2009 | 138 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 554 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1849 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 958 | 0.030 |
Why?
| | Genetic Variation | 1 | 2023 | 990 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 561 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 501 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6158 | 0.030 |
Why?
| | Feces | 1 | 2021 | 481 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 984 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 509 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 1232 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 699 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1934 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 319 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 91 | 0.030 |
Why?
| | Electrocardiography | 1 | 2009 | 610 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 741 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3636 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 795 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 427 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2009 | 559 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 195 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1448 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2830 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 5884 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2745 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1645 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 309 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 172 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 397 | 0.020 |
Why?
| | Pedigree | 1 | 2014 | 510 | 0.020 |
Why?
| | RNA | 1 | 2009 | 925 | 0.020 |
Why?
| | Anthropometry | 1 | 2013 | 213 | 0.020 |
Why?
| | Fruit | 1 | 2013 | 146 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3029 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17828 | 0.020 |
Why?
| | Vegetables | 1 | 2013 | 161 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 270 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 96 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 259 | 0.020 |
Why?
| | Dietary Fats | 1 | 2013 | 301 | 0.020 |
Why?
| | Liver | 1 | 2009 | 1807 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 377 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 202 | 0.020 |
Why?
| | Energy Intake | 1 | 2013 | 506 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1730 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 243 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 730 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2962 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3313 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5801 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2030 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2791 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 33782 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1423 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2849 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 782 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1457 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2697 | 0.010 |
Why?
|
|
Kelsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|